Io Biotech Inc (IOBT) - News Archive

At the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), IO Biotech presented compelling pre-clinical data on its additional therapeutic cancer vaccine candidates. This research highlights the compa...

: The Phase 3 trial evaluating the combination of Cylembio and pembrolizumab (KEYTRUDA) for first-line treatment in patients with advanced melanoma reported promising results at the European Society for Medical Oncology...

IO Biotech Announces Promising Data in Advanced Melanoma at ESMO Congress 2025 Amid Financial Performance Challenges IO Biotech Inc. has made a notable scientific achievement with its recent announcement that a late-bre...

In a groundbreaking development for the treatment of metastatic non-small cell lung cancer (NSCLC), IO Biotech has reported positive results from its Phase 2 IOB-022 study, evaluating the efficacy and safety of its off-...

The field of oncology has seen remarkable advancements over the past decade, particularly in the domain of immunotherapy. One area of significant interest is advanced head and neck cancer (HNC), which often presents a c...

In an epoch characterized by unprecedented advancements in the field of medicine, the emergence of novel therapeutic modalities inspires both hope and rigorous scrutiny among the discerning scholar-practitioners dedicat...

New York, July 25, 2024 In a significant advancement for cancer treatment, IO Biotech (Nasdaq: IOBT), a pioneering clinical-stage biopharmaceutical company, has announced that new data from its innovative head and neck...

The accepted abstract details the ongoing research on the IO102-IO103 vaccine candidate, a cornerstone in the company s pipeline. The IO102-IO103 is considered a groundbreaking approach in cancer therapeutics. It levera...

IO Biotech Expands Senior Leadership Team to Drive Commercialization Readiness Despite Cumulative Net LossesIO Biotech Inc, a leading biotechnology company in the healthcare sector, has recently announced the expansion...

:This article presents an in-depth analysis of the groundbreaking research conducted by IO Biotech, as presented at AACR 2024. The focus revolves around the new data provided on IO102-IO103, a novel cancer vaccine that...

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket TrialIO Biotech, a leading biotechnology company focused on developing novel immune-oncology therapies, has recently announced...